The Dutch pharmacist group Meijer has announced that it will not issue new prescriptions for brand-name drugs following the US announcement that the Food and Drug Administration (FDA) had banned some generic drugs.
In a statement, Meijers said that it “does not have the authority to change the regulations or to issue new approvals for new products”.
The company has long warned that the restrictions would cause delays in its supply chain, which accounts for about half of its sales.
Its spokesman, Simon Hildebrandt, said: “We do not have any choice but to not accept new orders or approvals for any drugs that we have received in the past.”
We have a duty to the patient and to the company to comply with the law and our commitment is that no new orders are to be issued for any brand-new drugs that Meijeri is now considering to withdraw from the market.
“It is only a matter of time before the Feds decide to lift the moratorium on new approvals.”
That will lead to the loss of jobs and jobs will be lost for years.
“Meijer is the world’s largest manufacturer of prescription drugs, which it sells to about 1.6 million pharmacies across the world.
The company’s pharmacy network employs about 4,000 people in the Netherlands, Austria, the Netherlands and Belgium.
The US Food and Safety Agency said that in a ruling that was “not without its flaws”, it had blocked certain generic drugs from being approved by the FDA in the US.
The agency has said that generic drugs were already safe when they were first approved in the late 1990s.
The FDA has also said that the agency had not determined which drugs were safe.
The decision to suspend the approvals of some generic medications was criticised by consumer groups and some health organisations.